Profile

Cover photo
Lymphoma Research Foundation
134 followers|23,604 views
AboutPostsPhotosYouTube

Stream

 
Lymphoma is the most common blood cancer in adults and the third most common cancer overall in children. According to the American Cancer Society, there are approximately 200 Americans diagnosed with #lymphoma every day. 

To raise critical funds for lymphoma research, LRF will host its annual #Lymphomathon (non-competitive 5K walk) in various cities throughout the U.S. 

Visit www.lymphomathon.org to learn more about the Lymphomathon program and to find one near you.
1
Add a comment...
 
The 2013 American Society of #Clinical #Oncology (ASCO) Annual Meeting, held last month in Chicago, brought together more than 25,000 oncology professionals and patient advocates from a broad range of specialties, making it an excellent venue for exploring the meeting’s theme, "Building Bridges to Conquer #Cancer.” 

The meeting offered innovative #scientific presentations and comprehensive educational content, including several new breakthroughs in the treatment of #lymphoma. Many of these initiatives were led by members of the LRF Scientific Advisory Board. Read about their contributions and presentations from the meeting. 

Learn more: http://www.lymphoma.org/site/pp.asp?c=bkLTKaOQLmK8E&b=8745761
4
1
Helder Felix's profile photo
Add a comment...
 
A study led by LRF #Scientific Advisory Board (SAB) member, Ari Melnick, MD, of Weill Cornell #Medical College, suggests a new class of drug inhibitors may affect a broader range of #lymphoma #patients than originally thought.

The study's results should ultimately lead the way to a new targeted #therapy for a wide range of #lymphomas, the most common #blood #cancer.

Learn more: http://www.lymphoma.org/site/pp.asp?c=bkLTKaOQLmK8E&b=8724331
6
1
Rachel Vistein's profile photo
Add a comment...
 
A trial conducted by researchers at the National Cancer Institute (NCI), including two members of LRF's Scientific Advisory Board, may point the way towards treating mediastinal B-cell lymphoma patients without radiation. http://www.lymphoma.org/site/pp.asp?c=bkLTKaOQLmK8E&b=8701615
2
Robby Hernandez's profile photo
 
this is a remarkable news, i hope they will  find some more positive results and testing. 
Add a comment...
 
This month's featured researcher, Stephanie A. Gregory. MD, FACP, is the Elodia Kehm Chair of Hematology and Professor of Medicine and Director of the Lymphoma Program at +Rush University Medical Center  in Chicago, IL. 

Dr. Gregory's academic career has been devoted to patient care, clinical research, and administration. Learn more about her here: http://www.lymphoma.org/site/pp.asp?c=bkLTKaOQLmK8E&b=8684587
2
Add a comment...
Have them in circles
134 people
Marita Poll's profile photo
Andy Eldridge's profile photo
Nancy Ruth's profile photo
Rod Cowan's profile photo
Denise Ambrusko's profile photo
 
The North American Educational Forum on Lymphoma is the most comprehensive lymphoma-specific educational conference in North America! This 2 ½ day annual program provides critical information on treatment options, patient support issues, clinical trials and the latest advances in lymphoma research to people with lymphoma and their loved ones.
1
Add a comment...
 
LRF Scientific Advisory Board Member and ‎#medical oncologist in the Adult ‎#Lymphoma Program at +Dana-Farber Cancer Institute   /Brigham and Women’s Cancer Center, Dr. Ann LaCasce, describes the various lymphoma treatment options in “Overview of Therapy of Lymphoma,” a presentation that summarizes the past, present and future of lymphoma therapy.

Read more and view the slide presentation here: 
http://blog.dana-farber.org/insight/2013/07/an-overview-of-lymphoma-therapy/
1
Add a comment...
 
Dr. Anas Younes , a #Lymphoma Research Foundation (LRF) #Scientific Advisory Board member, discusses treatment options for #Hodgkin lymphoma, the importance of clinical trials and his involvement with LRF. 

http://www.focusonhl.org/content/conversation-about-hodgkin-lymphoma-dr-anas-younes
1
Add a comment...
 
:: DRUG APPROVAL UPDATE::
The U.S. Food and Drug Administration (FDA) approved lenalidomide (Revlimid) for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies.

Lenalidomide currently represents the first and only oral therapy for mantle cell lymphoma.

To learn more about lenalidomide and clinical trial information: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm355438.htm?source=govdelivery
1
Add a comment...
 
"I would advise every patient who is newly diagnosed to be careful when doing research because you are not a statistic. I sure wasn't. Everybody is different, and keeping a positive attitude can make a difference. There’s always hope."

Moira, diagnosed with anaplastic large-cell lymphoma in 2000, shares her lymphoma journey and why she decided to get involved with LRF. 

http://www.lymphoma.org/site/pp.asp?c=bkLTKaOQLmK8E&b=8633291
2
Robby Hernandez's profile photo
 
There's hope, you are a true inspiration!
Add a comment...
People
Have them in circles
134 people
Marita Poll's profile photo
Andy Eldridge's profile photo
Nancy Ruth's profile photo
Rod Cowan's profile photo
Denise Ambrusko's profile photo
Contact Information
Contact info
Phone
800-500-9976
Email
Story
Tagline
Eradicate lymphoma and serve those touched by this disease
Introduction
The Lymphoma Research Foundation (LRF) is the nation's largest non-profit organization devoted exclusively to funding innovative lymphoma research and providing people with lymphoma and healthcare professionals with critical information on the disease. To date, LRF has awarded more than $51 million in lymphoma-specific research. For additional information on LRF’s programs and services, visit lymphoma.org.